The influence of smoking on the serum level of duloxetine

被引：40

作者：

Fric, M. ^{[1
]}

Pfuhimann, B. ^{[2
]}

Laux, G. ^{[1
]}

Riederer, P. ^{[2
]}

Distler, G. ^{[1
]}

Artmann, S. ^{[1
]}

Wohischlaegier, M. ^{[1
]}

Liebmann, M. ^{[1
]}

Deckert, J. ^{[2
]}

机构：

[1] Inn Salzach Hosp, Wasserburg A Inn, Germany

[2] Univ Clin Wurzburg, Dept Psychiat & Psychotherapy, Wurzburg, Germany

来源：

PHARMACOPSYCHIATRY | 2008年 / 41卷 / 04期

关键词：

D O I：

10.1055/s-2008-1073173

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Duloxetine is a dual acting antidepressant (selective serotonin and norepinephrine reuptake inhibitor). Existing data suggest that the advisable therapeutic serum level of duloxetine ranges between 20 and 80 ng/mL. In a naturalistic setting we determined duloxetine serum levels within a steady state in a sample of depressive inpatients by high performance liquid chrornatography (HPLC). The mean serum levels in 28 patients at [lie time of the first TDM analysis were 52.0 +/- 67ng/mL. Eight of the patients were smokers and showed a considerably lower serum level of 24.3 +/- 18.8 ng/mL. In the further Course of treatment the difference was compensated by application of higher doses in smokers. These findings suggest that smoking is associated with lower duloxetine serum levels due to an induction of CYP1A2 by polycylic hydrocarbons which are contained in tobacco smoke. Therefore in smokers higher doses of duloxetine (about 15%) seem to Lie necessary to reach adequate serum levels.

引用

页码：151 / 155

页数：5

共 33 条

[11] Time response of cytochrome P450 1A2 activity on cessation of heavy smoking
Faber, MS
Fuhr, U
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 178 - 184
[12] Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia
George, TP
Ziedonis, DM
Feingold, A
Pepper, WT
Satterburg, CA
Winkel, J
Rounsaville, BJ
Kosten, TR
[J]. AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (11) : 1835 - 1842
[13] Duloxetine in the treatment of depression - A double-blind-placebo-controlled comparison with paroxetine
Goldstein, DJ
Lu, YL
Detke, MJ
Wiltse, C
Mallinckrodt, C
Demitrack, MA
[J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (04) : 389 - 399
[14] Hiemke C, 2006, PSYCHOPHARMAKOTHERAP, V13, P12
[15] Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers
Ishigooka, J
Nagata, E
Takahashi, A
Sugiyama, T
Uchiumi, M
Tsukahara, T
Murasaki, M
Miura, S
Oguma, T
Yano, Y
[J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1997, 58 (10): : 679 - 692
[16] Iyengar S, 2002, EUR NEUROPSYCHOPHARM, V12, pS215
[17] Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects
Lantz, RJ
Gillespie, TA
Rash, TJ
Kuo, F
Skinner, M
Kuan, HY
Knadler, MP
[J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (09) : 1142 - 1150
[18] Lott RS, 2003, ADV PHARMACOL, V1, P228
[19] Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial
Millard, RJ
Moore, K
Rencken, R
Yalcin, I
Bump, RC
[J]. BJU INTERNATIONAL, 2004, 93 (03) : 311 - 318
[20] Müller WE, 2004, PSYCHOPHARMAKOTHERAP, V11, P71

← 1 2 3 4 →